A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
A phase 2/3 trial testing Navlimetostat in pancreatic ductal adenocarcinoma, active and no longer recruiting.
Overview
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) is a phase 2/3 interventional study registered as NCT07076121, led by Bristol-Myers Squibb, and active but no longer recruiting when checked on 2026-09-11. Official title: A Randomised, Phase 2/3 Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion. Planned enrolment is 470 participants (estimated). The study started in 2025-10-23 and primary completion is expected in 2029-05-03. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Shares Navlimetostat, Bristol Myers Squibb and the tag ctgov-ingest.
- TrialA Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Shares Bristol Myers Squibb and the tag ctgov-ingest.
- TrialA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Shares Bristol Myers Squibb and the tag ctgov-ingest.
- TrialA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS)
Shares Bristol Myers Squibb and the tag ctgov-ingest.
- TrialStudy of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.